Media coverage
69
Media coverage
Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet PR Newswire Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108529719&p=1gw&v=1&x=xqPlgH-jfBNCCfkTqcaSZQ Persons Scott Friedman Title Chemomab Therapeutics (CMMB) Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial Media name/outlet Street Insider Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108499854&p=1gw&v=1&x=UYU9CD8AkbTpWKVdlT6kOA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Street Insider Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108533567&p=1gw&v=1&x=jkncFZtzIz2IeYP-Rsp-KQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet BioSpace Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108942707&p=1gw&v=1&x=XmDvqpXrpiXEs7SWf8F2KQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet ADVFN UK Country/Territory United Kingdom Date 21/06/23 URL ct.moreover.com/?a=51108539808&p=1gw&v=1&x=ldklKBxkzUDEkXI0_lDeDg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Yahoo! Finance Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108624194&p=1gw&v=1&x=R_jwublglall5bxvuGA6sw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Spoke.com Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108539427&p=1gw&v=1&x=n8ac8lBGXRklvw050iB2rQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Southwest Daily News Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108557460&p=1gw&v=1&x=gJ8P4PGT-FvQU1GDdNAF8g Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Greenville Business Magazine Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108582704&p=1gw&v=1&x=0gBujmJCR03AN_uDxGChKA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Canadian Insider Country/Territory Canada Date 21/06/23 URL ct.moreover.com/?a=51108675616&p=1gw&v=1&x=XTJaSzW-1W6dBeQzxKrs1g Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Investors Hub Country/Territory United Kingdom Date 21/06/23 URL ct.moreover.com/?a=51109178174&p=1gw&v=1&x=6NerrTBy77bA-XrcdyXMmg Persons Scott Friedman Title Chemomab Therapeutics: Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 (Millistream) Media name/outlet Avanza Bank AB Country/Territory Sweden Date 21/06/23 URL ct.moreover.com/?a=51108492361&p=1gw&v=1&x=tod0mPBeKgGLkboQXNePRw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Leesville Leader Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108505902&p=1gw&v=1&x=bbD-g28p2_GazeaUm3n2qw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Riverton Journal Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108508578&p=1gw&v=1&x=_5Ag7V7UUy4NdlaozZ1G6g Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Clemmons Courier Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108512569&p=1gw&v=1&x=Afypu-RwmtYXYVguaEKzdA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet MillisMedway - Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108513212&p=1gw&v=1&x=PTSBq9PHhYIx_NCPhZam6A Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet TheTidewaterNews.com Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108526401&p=1gw&v=1&x=Ctn5isYpxwZ996crgFR7yg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Ashland - Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108527007&p=1gw&v=1&x=TcYG_AU72XRMoo4d2B1bGA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Lowndes Signal Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108528516&p=1gw&v=1&x=CvAHh6qZDc1L-n10L4J-pQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet ValleyTimes-News.com Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108529466&p=1gw&v=1&x=lhK1vQWA5LC7L8y7q_HElQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Leader Publications Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108530191&p=1gw&v=1&x=MOw5JAGX6URU_c7kaCA6Xg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Luverne Journal Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108530444&p=1gw&v=1&x=KpqZBFr94pjM7ppyZY8b1g Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Smithfield Times Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108536992&p=1gw&v=1&x=hM4ynN2bheZM3poRddNeiQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Middlesboro News Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108537510&p=1gw&v=1&x=eJC7TWKjG1jxp23C0LeWkw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Washington Daily News Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108537526&p=1gw&v=1&x=F8LHomyMGfAO_Tc2q_hCQQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Greenville Advocate Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108537531&p=1gw&v=1&x=orl6u2VLGHf_PBr-kEv-Hw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Jessamine Journal Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108538900&p=1gw&v=1&x=c4MtZP7jxUDBvYLSAKfk7g Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet BluegrassLive.com Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108539123&p=1gw&v=1&x=x6ai7NouudSTR-tMBZWq1A Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Andalusia Star Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108539555&p=1gw&v=1&x=kL2DEgkl5pQpQLSLTReozg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Roanoke Chowan News Herald Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108540293&p=1gw&v=1&x=4OWMMsYG_Fo7iWwMyxn2Ng Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Bogalusa Daily News Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108540413&p=1gw&v=1&x=YKlU6X9zLbmJkFTmM3TvMA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Stanly News & Press Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108540911&p=1gw&v=1&x=R5104rbXt3ukb_m4P0lpmQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Holliston - Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108541628&p=1gw&v=1&x=YoSxPmKrrK1dRK1DTUgS-Q Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Hopedale - Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108541656&p=1gw&v=1&x=GjW_NT7U3qXf_uBy_ldCAw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Norwood - Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108541682&p=1gw&v=1&x=XEXYgJMSytD18Od1lQXTDA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Salisbury Post Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108545482&p=1gw&v=1&x=G6aSzlneLcAevh1OnPkKgQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Atmore Advance Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108545886&p=1gw&v=1&x=aGHJn7UrHUUDfBJVYeocFg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Magnolia State Live Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108545900&p=1gw&v=1&x=q5VGzl6hAk1MA1JBrXuXNg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Davie County Enterprise Record Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108546735&p=1gw&v=1&x=NxPObuvQIYU8KgL_JB9bEg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet NorfolkWrentham - Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108547008&p=1gw&v=1&x=hPSyodG0d9dBxR6oNsMTYg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Demopolis Times Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108548912&p=1gw&v=1&x=OTxRC3FlP80Tsmzh5KXHTg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Orange Leader Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108548927&p=1gw&v=1&x=z3_e5qIqDHMaTfNQ4HLadA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Kenbridge Victoria Dispatch Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108549821&p=1gw&v=1&x=PpZ021x5LcWU56DhaocqdA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Farmville Herald Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108550054&p=1gw&v=1&x=HBm8_qzzzXHC_VkKw3HS8w Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Daily Leader.com Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108550847&p=1gw&v=1&x=3V2dnBft0AcGFPpThTQTFg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Charlotte Gazette Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108550900&p=1gw&v=1&x=Q2b_WrSZ4ejt-721P5TBbQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Clanton Advisor Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108550942&p=1gw&v=1&x=cazeDeBg5d1NYGZUmi5P3Q Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Interior Journal Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108551625&p=1gw&v=1&x=3Fwhbof7dy0CV9VdC-15-A Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Chester County Press (Oxford, Pennsylvania) Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108553809&p=1gw&v=1&x=mi6g8zdZrh9gx-xBH-1Fug Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Shelby County Reporter Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108555837&p=1gw&v=1&x=YZQVYcE1EiumRAPcSEyFUw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Cordele Dispatch Country/Territory Georgia Date 21/06/23 URL ct.moreover.com/?a=51108556742&p=1gw&v=1&x=8GZ7S5o0TtHPzz2OnPpBEw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Troy Messenger Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108556965&p=1gw&v=1&x=UPyeEmVVnHEhqCiymGZ9Yw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Austin Daily Herald Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108557537&p=1gw&v=1&x=XNYquJoLK8zDNEsdWnSX-A Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Prentiss Headlight Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108560882&p=1gw&v=1&x=DtxJcLSOcWLzZYqMKEQFjA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Times of San Diego Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108563864&p=1gw&v=1&x=tgKuoDgND0G1w-XRwg1txA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet L' Observateur Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108565956&p=1gw&v=1&x=doJQ-KWqMQykxZU_ikmYnQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Coastland Times Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108567049&p=1gw&v=1&x=jMkYoCBKJE4v5DeVQGzBVg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Elizabethton.com Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108567095&p=1gw&v=1&x=2YNK66EkYSR_pYej72ZkHA Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Vicksburg Post Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108567260&p=1gw&v=1&x=fhoKkwfHZylySDb4FRmgCg Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet The Brewton Standard Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108568389&p=1gw&v=1&x=kERM5HyE3J-rMlBNGvV67Q Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Claiborne Progress Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108569131&p=1gw&v=1&x=Joud4DkpKfZt88Fe4opoDQ Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Franklin- Local Town Pages Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108569197&p=1gw&v=1&x=3XOV7YJ8QSWAywO4_oT86g Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Americus Times-Recorder Country/Territory Georgia Date 21/06/23 URL ct.moreover.com/?a=51108570960&p=1gw&v=1&x=UxflOm_QCG4zj6aBAm9Bsw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Post-Searchlight Country/Territory Georgia Date 21/06/23 URL ct.moreover.com/?a=51108581677&p=1gw&v=1&x=X_qh_jSklPKOh3q_Au9pfw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Alabama Now Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108582161&p=1gw&v=1&x=evpDBSTyqq79sSzSpEJw9A Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Gates County Index Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108583045&p=1gw&v=1&x=EJkf6NwUVfZJxDWLt8tbGw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Suffolk News Herald Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108583826&p=1gw&v=1&x=9GEcL3Bqn4eNYGaNA7-c-A Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Alexander City Outlook Country/Territory United States Date 21/06/23 URL ct.moreover.com/?a=51108591210&p=1gw&v=1&x=Be-4VTdYiSJxzUHH6JS5pw Persons Scott Friedman Title Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 Media name/outlet Central Charts Country/Territory France Date 21/06/23 URL ct.moreover.com/?a=51108554348&p=1gw&v=1&x=N-er_LXdB_b1jO7jWQYAkg Persons Scott Friedman